Similarly, in a recent randomized, double-blind, placebo-controlled study, the selective CRF1 antagonist GSK-GW876008 decreased brain regional activity associated with the emotional-arousal network during expectation of abdominal pain in IBS patients [14]. This evidence concerns the gene CRHR1 and irritable bowel syndrome.